Prototype midazolam autoinjector
Ended Other Transaction Agreement Awarded Last action
- Contract number
- W911QY2090014
- Awardee
-
Rafa Laboratories LTD UEI CKDNTKNDPMJ6
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $6,345,282
Award facts
- Contract value 84% obligated
-
- $6,530,739.30 Current, with exercised options
- $7,564,838.86 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- Israel
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $61,561 | |
| Supplemental Agreement for work within scope | $285,467 | |
| Funding Only Action | $1,306,723 | |
| Supplemental Agreement for work within scope | $343,600 | |
| Supplemental Agreement for work within scope | $56,330 | |
| Supplemental Agreement for work within scope | $2,945,103 | |
| Original award | $1,346,498 |
Show all 11
About this award
This federal contract award to Rafa Laboratories LTD, a foreign-owned for-profit manufacturer, is for the development of a prototype midazolam autoinjector. The contract, valued at $7,564,838.86, was awarded by the Department of the Army's Joint Program Executive Office for Chemical and Biological Defense under an Other Transaction Agreement. The contract does not have a set-aside designation.
Rafa Laboratories has previously provided medical countermeasures, including autoinjectors and training devices, to other U.S. federal agencies such as the Department of Health and Human Services. This current award is for the delivery of prototype midazolam autoinjectors, which are used as sedatives and anesthetic agents that can be self-administered through autoinjectors for chemical and biological defense programs. Additionally, Rafa Laboratories holds a $48.2 million Indefinite Delivery Vehicle from the Department of the Army's Joint Program Executive Office for Chemical and Biological Defense, awarded in December 2022, to procure Food and Drug Administration-approved midazolam autoinjectors.
Quick answers
Who was awarded contract W911QY2090014?
W911QY2090014 was awarded to Rafa Laboratories LTD by ACC Aberdeen Proving Ground (Army Contracting Command) on August 6, 2020.
How much is contract W911QY2090014 worth?
The government has obligated $6,345,282 on W911QY2090014. Its current value, with exercised options, is $6,530,739. Its potential value, with all options, is $7,564,839.
Which agency awarded contract W911QY2090014?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY2090014, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY2090014 competed?
The extent of competition for W911QY2090014 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award